Glaxo gets a Shingrix boost
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Glaxo needs long-acting HIV gamble to pay off
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
Gilead challenges Viiv in heavily treated HIV
And Gilead has plans for its biannual injection in pre-exposure prophylaxis, too.
Viiv’s HIV success shows PrEP is not everything
Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.
Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
